This report was recently updated on April 19 2024 with the latest and most recent
market numbers
Global Anterior Uveitis Treatment Market Size, Trends, and Analysis - Forecasts To 2026 By Treatment Type (Corticosteroids, Cycloplegic Agents, Anti-TNF Agents, Immunosuppressants); By Distribution Channel (Hospital, Retail, Online Pharmacies); By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis
Anterior uveitis is an infection of the middle layer of the retina, which consists of the iris (colored portion of the eye) & the ciliary muscle (adjacent tissue). Untreated anterior uveitis causes vision loss and serious eye injury, which may lead to retinal edema, cataract, or glaucoma. Anti-inflammatory eye drops should be used to relieve anterior uveitis. Treatment normally works better for it. Moreover, the disorder could have a proclivity to recur. Uveitis is a less-studied research symptom that can be treated with a variety of drugs, like biologics and corticosteroids. Corticosteroids were shown to be effective in curing the disease, and doctors are now looking at biological therapy for treating anterior uveitis. The advent of biologics for the diagnosis of uveitis, like Humira (Adalimumab), is propelling the anterior uveitis market in the Asia Pacific. Many firms engaged in the uveitis market, developing new medicines and extending clinical uses of approved drugs to include and successfully treat uveitis presents a major growth potential.
The rise in the prevalence of anterior uveitis and related complications worldwide, the high occurrence of autoimmune disorders globally, the spike in the development of biological drugs for the treatment of uveitis, the growing demand for advanced healthcare products, and the growing number of government efforts to reduce e-waste are all contributing to the market's growth. Furthermore, the ophthalmological industry has rapidly seen a surge in research & development activities for new drug exploration, which has contributed to the implementation of ideal therapeutics. As the amount of money spent on research and development grows, further clinical trials for curing eye inflammation are being conducted around the globe. Many new stage III clinical trials for the refractory post or moderate uveitis are in the works right now. This opens up a lot of doors for the anterior uveitis treatment industry to expand.
Furthermore, the market's prosperous players have been seen to focus heavily on technical advances and the accelerated launch of new and emerging products. As a result, ophthalmologists are working hard to develop new medication formulations that will minimize anterior uveitis and enable them to provide better ophthalmic treatment and patient care. In the clinical trial stage of development, this also leads to increased performance and safety profiles, resulting in a significant decrease in disease progression.
Other attributes like the rising geriatric population, the fast-track clearance of pipeline medicines, people's increasing disposable incomes combined with high healthcare spending, and the growing number of medical trials for eye inflammation treatment are all contributing to the market's development. In addition, the growing number of clinics, medical facilities, and online treatments are all helping to drive the development of the anterior uveitis treatment market.
Based on the treatment type, the anterior uveitis treatment market is divided into corticosteroids, cycloplegic agents, anti-tnf agents, and immunosuppressant. Corticosteroids have the leading position and are anticipated to rise at the fastest pace. They're used as eye drops and as part of a more comprehensive treatment plan. Corticosteroids can also be used in ocular implants. Prednisolone acetate, dexamethasone sodium phosphate, betamethasone, loteprednol, rimexolone, and fluorometholone are some of the most popular topical corticosteroid medications available.
Anti-TNF agents are often used as anti-inflammatory agents, while cycloplegic agents can be used for both diagnosis and treatment. Immunosuppressive medications, work by disrupting the immune system's natural activity to reduce inflammation. These medications are primarily used in cases of corticosteroid resistance or chronic uveitis.
Based on the distribution channel, the anterior uveitis treatment market can be divided into hospitals, retail, and online pharmacies. The Hospital generated the highest revenue share of this segment due to the use of a diverse variety of possibilities for treating eye inflammation. Furthermore since hospitals treat and care for a vast number of patients, healthcare facilities are a leading sector.
Online pharmacies are projected to expand rapidly over the forecast era, because of the ease of having medicines delivered to the doorstep. The market's rise is also fueled by the reduced prices offered by online pharmacies. Due to a recent wave of price increases in hospital pharmacies, their proximity provides a benefit.
Because of the disease's increasing prevalence in the United States, North America dominated the market in 2019. The presence of key players in the area is also driving this regional segment's rapid development. Some of the major driving factors are the development of new approaches for treating ocular disorders, such as stem cell therapy, and the approval of drugs such as Humira for the treatment of this disorder.
The Asia Pacific region is expected to hold the dominant share of the market. The region is anticipated to witness significant growth at a high rate during the forecast period as a result of several factors like the growing incidence of people with anterior uveitis in the region, the lack of sanitation for contagious diseases in developing countries, the awareness of different therapeutic intervention available in the area, and increasing government expenditure.
UCB Biopharma S.P.R.L.; Novartis AG; Sirion Therapeutics, Inc.; AbbVie Inc.; Santen Pharmaceutical Co., Ltd; Eyegate Pharmaceuticals, Inc.; Aldeyra Therapeutics, Inc.; Clearside Biomedical, Inc.; Lux Biosciences, Inc., and Aciont Inc.; are some of the top players in the Anterior Uveitis Treatment market.
Please note: This is not an exhaustive list of companies profiled in the report.
In February 2021, Alimera Sciences, Inc., a pharmaceutical company focused on the production and commercialization of prescription ophthalmic pharmaceuticals, announced that ILUVIEN is now available in Finland for diabetic macular edema (DME) and non-infectious uveitis affecting the posterior portion (NIPU), and will be sold by Alimera and distributed by Nordic Prime.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview And Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Global Anterior Uveitis Treatment Industry Overview, 2019-2026
2.1.1 Industry Overview
2.1.2 Product Overview
2.1.3 Type Overview
2.1.4 Regional Overview
Chapter 3 Global Anterior Uveitis Treatment Market Trends
3.1 market segmentation
3.2 Industry Background, 2019-2026
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 Rising incidence of optical infections
3.3.1.2 Rising disposable income
3.3.2 Industry Challenges
3.4 Prospective Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Technology Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Global Anterior Uveitis Treatment Market, By Treatment Type
4.1 Treatment Type Outlook
4.2 Corticosteroids
4.2.1 Market Size, By Region, 2019-2026 (USD Million)
4.3 Cycloplegic Agents
4.3.1 Market Size, By Region, 2019-2026 (USD Million)
4.4 Anti-TNF Agents
4.4.1 Market Size, By Region, 2019-2026 (USD Million)
4.5 Immunosuppressants
4.5.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 5 Global Anterior Uveitis Treatment Market, By Distribution Channel
5.1 Distribution Channel Outlook
5.2 Distribution Channel
5.2.1 Market Size, By Region, 2019-2026 (USD Million)
5.3 Retail Pharmacies
5.3.1 Market Size, By Region, 2019-2026 (USD Million)
5.4 Online Pharmacies
5.4.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 6 Global Anterior Uveitis Treatment Market, By Region
6.1 Regional outlook
6.2 North America
6.2.1 Market Size, By Country 2019-2026 (USD Million)
6.2.2 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.2.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.2.4 U.S.
6.2.4.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.2.4.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.2.5 Canada
6.2.5.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.2.5.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.3 Europe
6.3.1 Market Size, By Country 2019-2026 (USD Million)
6.3.2 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.3.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.3.4 Germany
6.3.4.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.3.4.1 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.3.5 UK
6.3.5.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.3.5.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.3.6 France
6.3.6.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.3.6.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.3.7 Italy
6.3.7.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.3.7.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.3.8 Spain
6.3.8.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.3.8.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.4 Asia Pacific
6.4.1 Market Size, By Country 2019-2026 (USD Million)
6.4.2 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.3.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.4.4 China
6.4.4.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.4.4.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.4.5 India
6.4.5.1 Market Size, By Treatment Type, 2019-2026 (USD Millio
6.4.5.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.4.6 Japan
6.4.6.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.4.6.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.4.7 Australia
6.4.7.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.4.7.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.4.8 South Korea
6.4.8.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.4.8.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.5 Latin America
6.5.1 Market Size, By Country 2019-2026 (USD Million)
6.5.2 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.3.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.5.4 Brazil
6.5.4.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.5.4.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.5.5 Mexico
6.5.5.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.5.5.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.5.6 Argentina
6.5.6.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.5.6.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.6 MEA
6.6.1 Market Size, By Country 2019-2026 (USD Million)
6.6.2 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.6.4 Saudi Arabia
6.6.4.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.6.4.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.6.5 UAE
6.6.5.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.6.5.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.6.6 South Africa
6.6.6.1 Market Size, By Treatment Type, 2019-2026 (USD Million)
6.6.6.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
Chapter 7 Company Landscape
7.1 Competitive Analysis, 2020
7.2 Novartis AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Strategic Positioning
7.2.4 Info-Graphic Analysis
7.3 Santen Pharmaceutical Co., Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Strategic Positioning
7.3.4 Info-Graphic Analysis
7.4 AbbVie Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Strategic Positioning
7.4.4 Info-Graphic Analysis
7.5 Eyegate Pharmaceuticals, Inc
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Strategic Positioning
7.5.4 Info-Graphic Analysis
7.6 Clearside Biomedical, Inc
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Strategic Positioning
7.6.4 Info-Graphic Analysis
7.7 Aldeyra Therapeutics, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Strategic Positioning
7.7.4 Info-Graphic Analysis
7.8 Aciont Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Strategic Positioning
7.8.4 Info-Graphic Analysis
7.9 Sirion Therapeutics, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Strategic Positioning
7.9.4 Info-Graphic Analysis
7.10 UCB Biopharma S.P.R.L.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Strategic Positioning
7.10.4 Info-Graphic Analysis
7.11 Lux Biosciences, Inc.
7.11.1 Company Overview
7.11.2 Financial Analysis
7.11.3 Strategic Positioning
7.11.4 Info-Graphic Analysis
7.12 Other Companies
7.12.1 Company Overview
7.12.2 Financial Analysis
7.12.3 Strategic Positioning
7.12.4 Info-Graphic Analysis
The Global Anterior Uveitis Treatment Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Anterior Uveitis Treatment Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
